恩度联合DP方案治疗晚期肺鳞癌的效果

Effect of Endostar Combined with DP Regimen in the Treatment of Advanced Lung Squamous Cell Carcinoma

目的探讨恩度联合多西他赛和顺铂(DP)方案治疗晚期肺鳞癌的效果。方法选择2017年11月至2019年11月驻马店市中心医院收治的120例晚期肺鳞癌患者作为研究对象,按随机数表法分为对照组(60例)与观察组(60例)。对照组接受DP方案化疗治疗,观察组接受恩度联合DP方案化疗治疗,均连续治疗4个周期。治疗4个周期后,比较两组近期疗效、肿瘤标志物[癌胚抗原(CEA)、糖抗原125(CA125)]、治疗期间药物毒副作用;随访1 a,比较两组患者生存情况。结果治疗4个周期后,观察组总有效率高于对照组,差异有统计学意义(P<0.05);治疗4个周期后,两组CEA、CA125水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗期间,两组肝功能损伤、白细胞减少、血小板数目减少及恶心呕吐发生率比较,差异无统计学意义(P>0.05);对照组存活33例,病死27例,总体生存时间为11.250个月(95%CI:10.651~11.849个月);观察组存活44例,病死16例,总体生存时间为11.283个月(95%CI:10.928~11.638个月),观察组患者生存率高于对照组,差异有统计学意义(P<0.049)。结论对晚期肺鳞癌应用恩度联合DP方案治疗可提高近期效果,降低CEA、CA125水平,且不增加药物毒副作用,可降低1 a内病死率。

Objective To investigate the effect of Endostar combined with Docetaxel and Cisplatin(DP)in the treatment of advanced lung squamous cell carcinoma.Methods A total of 120 patients with advanced lung squamous cell carcinoma admitted to Zhumadian Central Hospital from November 2017 to November 2019 as the study subjects,they were divided by a random number table method into control group(60 cases)and observation group(60 cases).The control group received DP regimen for chemotherapy,and the observation group received Endostar combined with DP regimen for chemotherapy,all patients were treated continuously for 4 cycles.After 4 cycles of treatment,the short-term efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)]and toxic and side effects during treatment were compared between the two groups;followed up for 1 year,the survival of patients in the two groups was compared.Results After 4 cycles of treatment,the total effective rate(ORR)of the observation group was higher than that of the control group(P<0.05);after 4 cycles of treatment,the levels of CEA and CA125 in both groups were lower than before treatment,and the observation group was lower than the control group(P<0.05);during treatment,there was no statistical difference in the incidence of liver function injury,leucopenia,thrombocytopenia,nausea and vomiting between the two groups(P>0.05);in the control group,33 cases survived and 27 cases died from illness,the overall survival time was 11.250 months(95%CI:10.651-11.849 months);in the observation group,44 cases survived and 16 cases died from illness,the overall survival time was 11.283 months(95%CI:10.928-11.638 months),the survival rate of the observation group was higher than that of the control group(P<0.049).Conclusion Endostar combined with DP regimen in the treatment of advanced lung squamous cell carcinoma can improve the short-term curative effect and reduce the levels of CEA and CA125,and it will not increase the toxic and side effects of drugs and can reduce the mortality within one year.